DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0272636A1 Byrd Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/0272636A1 Byrd Et Al US 20100272636A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0272636A1 Byrd et al. (43) Pub. Date: Oct. 28, 2010 (54) ANTI-CD74 IMMUNOCONJUGATES AND filed on Mar. 1, 2002, provisional application No. METHODS OF USE 61/265,999, filed on Dec. 2, 2009. (75) Inventors: John C. Byrd, Columbus, OH Publication Classification (US); David M. Goldenberg, (51) Int. Cl. Hansen, Picayune, MS (US) A 6LX 9/27 (2006.01) A6II 5L/12 (2006.01) SISNOSE RNc. A61K 38/19 (2006.01) 3OO AMERICAN ROAD A638/2A638/20 :08:2006.O1 MORRIS PLAINS, NJ 07950 (US) A6IP35/00 (2006.01) (73) Assignees: THE OHO STATE 39t. E: 308: UNIVERSITY, Columbus, OH A6IP37/06 (2006.015 (US); IMMUNOMEDICS, INC., Morris Plains, NJ (US) (52) U.S. Cl. ..................... 424/1.21; 424/450; 424/178.1; 424/179.1; 424/183.1; 424/85.1; 424/85.2: (21) Appl. No.: 12/789,575 424/85.4; 424/85.5; 424/85.6; 424/85.7 (22) Filed: May 28, 2010 (57) ABSTRACT O O Disclosed are compositions that include anti-CD74 immuno Related U.S. Application Data conjugates and optionally a therapeutic and/or diagnostic (63) Continuation-in-part of application No. 10/706,852, agent. In preferred embodiments, the immunoconjugates filed on Nov. 12, 2003, which is a continuation-in-part comprise one or more anti-CD74 antibodies or antigen-bind of application No. 10,314 330, filed on Dec. 9, 2002 ing fragments thereof, conjugated to a liposome or micelle. which is a continuation of application No. 09/965,796, Also disclosed a methods for preparing the immunoconju filed on Oct. 1, 2001, which is a continuation of appli- gates and using the immunoconjugates in diagnostic and cation No. 09/307,816, filed on May 10, 1999, now therapeutic procedures. In certain preferred embodiments, Pat. No. 6 306 393. said application No. 10,706 852 is the therapeutic methods comprise administering to a subject a continuation-in-part of application No. 10/350,096, with a CD74-expressing disease al anti-CD74 immunocon filed on Jan. 24, 2003, which is a continuation of appli- jugate and thereby inducing apoptosis of CD74-expressing cation No. 09/590,284 filed on Jun. 9, 2000, now Pat. cells. In more preferred embodiments, the CD74 immuno No. 7074,403 said application No. 10,706 852 is a conjugate is capable of inducing cell death in the absence of continuation-in-part of application No. 10/377,122, any other therapeutic agent, although Such agents may be filed on Mar. 3, 2003, now Pat. No. 7,312.318 optionally administered prior to, together with or Subsequent • - s s • L vs - s- a 1- s- u Y- - to administration of the anti-CD74 immunoconjugate. The (60) Provisional application No. 60/478,830, filed on Jun. compositions may be part of a kit for administering the anti 17, 2003, provisional application No. 60/360,259, CD74 immunoconjugates or compositions. Patent Application Publication Oct. 28, 2010 Sheet 1 of 11 US 2010/0272636 A1 06 O8VÌ280$30£.09 +--~~~~----–—~~+–+~---+-+~~--~~~~-->•+~~~~+-~~+– 0£02O? +–~~~~~~~+–+~-+-~~+–+----+––-+ +~––+~~~~-~---+~-+-+–+--+- +–~~+~~~~~~+–+~--–+----–-+--------- O[IX{T06{{\f00 VI"OIH V?Zg0GO? ZHGIOTYICIO £&ICIO Patent Application Publication Oct. 28, 2010 Sheet 2 of 11 US 2010/0272636 A1 D8VÌLZOZ0I 0$3[+–~~+–+--------–+~~~~---+~~+–+-------~--~~~~+ OLZ+~+–~~~+--~---{---–+~~~~~~+--~---------+- 06+––+--------–+~~~~~~~+----~~~~ L0980O £€––+~~+~---------–+----+----—- £0£TH0G0CI I06O I?a"IyI,9,0?T?T?T?T?TSSTS-53); Z?OTOTRICHO €YICIO Patent Application Publication Oct. 28, 2010 Sheet 3 of 11 US 2010/0272636 A1 6G O8T 68 ÇIT -~+--+-~~~~~~-----+––+–-+----+----------+ ––+~+------~+–+------–+ “?IHVZ ~~–+–~-~~+-~~+~~+-–+-+–+---+- IQSGI HA?TT3 ZHOTOTA?CIO Patent Application Publication Oct. 28, 2010 Sheet 4 of 11 US 2010/0272636 A1 06 G G8 ITog/III6? O8T+––+-+–+–~~+–+---- 0L2+~~------+-–+--~-----+-----––+~+~-+-----+~+ I*XIIT».I,9&T?T?TAT?TSTST?TS3);30 £&ICIO 9+–+69 MALT"|0 ZHOTOIYICIO Patent Application Publication Oct. 28, 2010 Sheet 7 of 11 US 2010/0272636 A1 6G 69 O8T O9£ ©I V†“?IH +--------––+~~---+--+--+~---++––+~+–+------------------ +–~---+~~----+~+–+–~+----~~~~~ +–~~+~~+------–+-------------–+~+~~--------–—+ +–~---+~~--~+~~~~+–+~--+–~+~ £ICIO HA?TTUI ZAICIOTxICIO Patent Application Publication Oct. 28, 2010 Sheet 8 of 11 US 2010/0272636A1 06 I09 GG LZO T80 A"IS –~--------+----~~+----------------+–+~–+-~~++––+ –—–+--------~~+–··-----+----+-–+~~+-~-+––+- –+---+----------~––+--+–+–+------------+------+-+–-~~- –+-+----------+---------+----------+------------- XHALTITUI —º—THOTO Patent Application Publication Oct. 28, 2010 Sheet 9 of 11 US 2010/0272636 A1 8IS“?IJI (snou va) amisodid% |- VS"OIH |Ir|Ir] 8ASO Patent Application Publication Oct. 28, 2010 Sheet 10 of 11 US 2010/0272636 A1 easo One S-pers Aften OAO + Wee. ano + 34-gue oneSen? A?esin eur OAD + V ele w ele-- OAO + 3-rule + eIN oute + ew OAO + 3-le le: Patent Application Publication Oct. 28, 2010 Sheet 11 of 11 US 2010/0272636 A1 TH-961euosodinpeyeenum 09"?IJI W 000 US 2010/0272636 A1 Oct. 28, 2010 ANT-CD74. IMMUNOCONUGATES AND bind to a known tumor associated antigen (TAA) or to an METHODS OF USE antigen associated with infectious diseases or other disease States. CROSS-REFERENCE TO RELATED 0006. One such tumor-associated antigen is CD74, which APPLICATIONS is an epitope of the major histocompatibility complex (MHC) 0001. This application is a continuation-in-part of appli class II antigen invariant chain, Ili, present on the cell Surface cation Ser. No. 10/706,852, filed Nov. 12, 2003, which and taken up in large amounts of up to 8x10" molecules per claimed the benefit under 35 U.S.C. 119(e) of provisional cell per day (Hansen et al., 1996, Biochem. J., 320: 293-300). application Ser. No. 60/478,830, filed on Jun. 17, 2003, and CD74 is present on the cell surface of B-lymphocytes, mono which was a continuation-in-part of application Ser. No. cytes and histocytes, human B-lymphoma cell lines, melano 10/314,330, filed on Dec. 9, 2002, which was a continuation mas, T-cell lymphomas and a variety of other tumor cell of application Ser. No. 09/965,796, filed on Oct. 1, 2001, types. (Hansen et al., 1996, Biochem.J.,320:293-300) CD74 which was a continuation of application Ser. No. 09/307,816, associates with C/B chain MHC II heterodimers to form MHC filed on May 10, 1999, now U.S. Pat. No. 6,306.393. U.S. Ser. II CBIi complexes that are involved in antigen processing and No. 10/706,852 was also a continuation-in-part of application presentation to T cells (Dixon et al., 2006, Biochemistry Ser. No. 10/350,096, filed on Jan. 24, 2003, which was a 45:5228-34; Loss et al., 1993, J Immunol 150:3187-97: continuation of application Ser. No. 09/590,284, filed on Jun. Cresswell et al., 1996: Cell 84:505-7). 9, 2000, now U.S. Pat. No. 7,074,403. U.S. Ser. No. 10/706, 0007 CD74 also plays an important role in cell prolifera 852 was also a continuation-in-part of application Ser. No. tion and Survival. Binding of the CD74 ligand, macrophage 10/377,122, filed on Mar. 3, 2003, now U.S. Pat. No. 7,312, migration inhibitory factor (MIF), to CD74 activates the 318, which claimed the benefit of provisional application Ser. MAP kinase cascade and promotes cell proliferation (Lenget No. 60/360,259, filed on Mar. 1, 2002. al., 2003, J Exp Med 197:1467–76). Binding of MIF to CD74 0002. This application claims the benefit under 35 U.S.C. also enhances cell survival through activation of NF-kB and 119(e) to provisional application Ser. No. 61/265,999, filed Bcl-2 (Lantner et al., 2007, Blood 110:4303-11). Dec. 2, 2009. All of the above-identified applications and 0008 Murine LL1 (mLL1 or murine anti-CD74 antibody) patents are incorporated herein by reference in their entire is a specific monoclonal antibody (mAb) reactive with CD74. ties. Cell surface-bound LL1 is rapidly internalized to the lysoso mal compartment and quickly catabolized, much faster than FEDERALLY FUNDED RESEARCH other antibodies, such as anti-CD19 or anti-CD22 (Hansen et 0003. This work was supported in part by National Cancer al., 1996, Biochem. J., 320: 293-300). LL1 was reported to Institute grants CA95426, CA103985 and CA81534-02. The exhibit the highest rate of accumulation inside B cells of any Federal Government may have certain rights in the invention. of the antibodies tested (Griffiths et al., 2003, Clin Cancer Res 9:6567-71). FIELD OF THE INVENTION 0009 Murine LL1 was developed by fusion of mouse myeloma cells with splenocytes from BALB/c mice immu 0004. The present invention concerns compositions and nized with preparations from the Raji B-lymphoma cell line methods of use of liposomes attached to targeting molecules, (called EPB-1 in Pawlak-Byczkowska et al., Can. Res., 49: Such as antibodies, antibody fragments or antibody fusion 4568 (1989)). The clinical use of mLL1, just as with most proteins. More particularly, the antibodies, fragments or other promising murine antibodies, has been limited by the fusion proteins may bind to a tumor associated antigen, infec development in humans of a human anti-mouse antibody tious disease associated antigen or other disease associated (HAMA) response. A HAMA response is generally not antigen. Even more particularly, the targeting molecule may observed following injection of mLL1 Fab', as evidenced in a bind to the invariant chain (Ii) of the HLA-DR complex, also bone marrow imaging study using an mLL1 Fab" labeled with known as CD74. An exemplary anti-CD74 antibody is mil "Tc. Juweidet al., Nuc. Med. Comm. 18: 142-148 (1997). atuZumab (hLL1). The antibody conjugated liposome is of However, in some therapeutic and diagnostic uses, a full use for the treatment of a variety of diseases, such as autoim length anti-CD74 antibody may be preferred. This use of the mune disease, immune dysregulation disease, cancer, lym full-length anti-CD74 antibody can limit the diagnostic and phoma, leukemia, chronic lymphocytic leukemia, follicular therapeutic usefulness of Such antibodies and antibody con lymphoma, diffused large B cell lymphoma, multiple jugates, not only because of the potential anaphylactic prob myeloma or non-Hodgkin’s lymphoma.
Load more

Recommended publications
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • Harmonised Bds Suppl 20070
    ABCDEF 1 EU Harmonised Birth Dates and related Data Lock Points, Supplementary list, 7 February 2007 Innovator brand name First DLP after Proposed Active substance name (INN) (for fixed combination 30 October Firm's Name Comments EU HBD products only) 2005 2 3 Aceclofenac 19900319 20080331 Almirall / UCB 4 Aciclovir 19810610 20060630 GSK 5 Adrafinil 19810710 20060131 Cephalon 6 Aldesleukine 19890703 20051231 Novartis NL=RMS Pfizer/Schwarz 7 Alprostadil (erectile dysfunction) 19840128 20080131 Pharma UK=RMS Alprostadil (peripheral arterial 19810723 20060731 Pfizer product differs from Schwarz Pharma 8 occlusive diseases) product Alprostadil (peripheral arterial 19841128 20051128 Schwarz Pharma product differs from Pfizer product 9 occlusive diseases) 10 Atenolol + chlorthalidone Tenoretic 19970909 20080908 AstraZeneca Azelaic acid 19881027 20060102 Schering AG / Pfizer AT = RMS 11 12 Aztreonam 19840804 20060803 BMS 13 Benazepril 19891128 20071130 Novartis Benazepril + hydrochlorothiazide Cibadrex 19920519 20070531 Novartis 14 15 Bisoprolol 19860128 20070930 Merck AG Bisoprolol + hydrochlorothiazide many product names 19920130 20061103 Merck AG 16 17 Botulinum Toxin A 19960906 20061030 Allergan currently 6-monthly PSURs 18 Brimonidine 19960906 20080930 Allergan UK=RMS 19 Brimonidine + timolol Combigan 19960906 20080930 Allergan UK=RMS 20 Bromperidol 20061115 J&J 21 Brotizolam 19830515 20071231 Boehringer Ingelheim 22 Budesonide 19920430 20070430 AstraZeneca 23 Budesonide + formoterol Symbicort 20000825 20070825 AstraZeneca 24 Buflomedil
    [Show full text]
  • Clinical Practice Guidelines for Diagnosis and Management Of
    REVIEWS Clinical Practice Guidelines for Diagnosis and Management of Hypersensitivity Reactions to Contrast Media Rosado Ingelmo A1, Doña Diaz I2, Cabañas Moreno R3, Moya Quesada MC4, García-Avilés C5, García Nuñez I6, Martínez Tadeo JI7, Mielgo Ballesteros R8, Ortega-Rodríguez N9, Padial Vilchez MA10, Sánchez-Morillas L11, Vila Albelda C1, Moreno Rodilla E12*, Torres Jaén MJ2* 1Unidad de Alergia, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain 2Allergy Unit, IBIMA-Regional University Hospital of Málaga, UMA, Málaga, Spain 3Department of Allergy, Hospital La Paz, Health Research Institute (IdiPAZ), Madrid, Spain 4Sección de Alergia CH Torrecárdenas, Almería, Spain 5Unidad de Alergia, Hospital Moncloa, Madrid, Spain 6Servicio de Alergología, Hospital Quirón Málaga, Málaga, Spain 7Servicio de Alergología, Hospital Universitario Ntra Sra de Candelaria, Santa Cruz de Tenerife, Tenerife, Spain 8Servicio de Alergología, Hospital Universitario 12 de Octubre, Madrid, Spain 9Servicio de Alergia, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain 10Servicio de Alergologia, Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain 11Servicio de Alergologia, Hospital Clínico San Carlos, Madrid, Spain 12Servicio de Alergología, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain *Both authors contributed equally to this study. On behalf of the Drug Allergy Committee of Spanish Society of Allergy and Clinical Immunology (SEAIC) J Investig Allergol Clin Immunol 2016; Vol. 26(3): 144-155 doi: 10.18176/jiaci.0058 Abstract The objective of these guidelines is to ensure efficient and effective clinical practice. The panel of experts who produced this consensus document developed a research protocol based on a review of the literature. The prevalence of allergic reactions to iodinated contrast media (ICM) is estimated to be 1:170 000, that is, 0.05%-0.1% of patients undergoing radiologic studies with ICM (more than 75 million examinations per year worldwide).
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • 3258 N:O 1179
    3258 N:o 1179 LIITE 1 BILAGA 1 LÄÄKELUETTELON AINEET ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN Latinankielinen nimi Suomenkielinen nimi Ruotsinkielinen nimi Englanninkielinen nimi Latinskt namn Finskt namn Svenskt namn Engelskt namn Abacavirum Abakaviiri Abakavir Abacavir Abciximabum Absiksimabi Absiximab Abciximab Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoninatrium Acediasulfonnatrium Acediasulfone sodium Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini Acetfenolisatin Acetphenolisatin Acetylcholini chloridum Asetyylikoliinikloridi Acetylkolinklorid Acetylcholine chloride Acetylcholinum Asetyylikoliini Acetylkolin Acetylcholini Acetylcysteinum Asetyylikysteiini Acetylcystein Acetylcysteine Acetyldigitoxinum Asetyylidigitoksiini Acetyldigitoxin Acetyldigitoxin Acetyldigoxinum Asetyylidigoksiini Acetyldigoxin Acetyldigoxin Acetylisovaleryltylosini Asetyyli-isovaleryyli- Acetylisovaleryl- Acetylisovaleryltylosine tartras tylosiinitartraatti tylosintartrat tartrate Aciclovirum Asikloviiri Aciklovir Aciclovir Acidum acetylsalicylicum Asetyylisalisyylihappo Acetylsalicylsyra Acetylsalicylic acid Acidum alendronicum
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • Scanned Using Fujitsu 6670 Scanner and Scandall Pro Ver 1.7 Software
    358 1998/74 MEDICINES AMENDMENT REGULATIONS 1998 THOMAS EICHELBAUM, Administrator of the Government ORDER IN COUNCIL At Wellington this 20th day of April 1998 Present: THE HON JENNY SHIPLEY PRESIDING IN COUNCIL PURSUANT to section 105 of the Medicines Act 1981, His Excellency the Administrator of the Government, acting by and with the advice and consent of the Executive Council, and on the advice of the Minister of Health tendered after consultation with the organisations and bodies that appeared to the Minister to be representative of persons likely to be substantially affected, makes the following regulations. ANALYSIS 1. Title and commencement SCHEDULE 2. New First Schedule substituted New First Schedule of Principal Regulations 3. Revocation 1998/74 Medicines Amendment Regulations 1998 359 REGULAnONS 1. Title and commencement-( 1) These regulations may be cited as the Medicines Amendment Regulations 1998, and are part of the Medicines Regulations 1984"- ("the principal regulations"). (2) These regulations come into force on 1 June 1998. 2. New First Schedule substituted-The principal regulations are amended by revoking the First Schedule, and substituting the First Schedule set out in the Schedule of these regulations. 3. Revocation-The Medicines Regulations 1984, Amendment No. 7 (S.R. 1996/367) are consequentially revoked. ·S.R. 1984/143 Amendment No.1: (Revoked by S.R. 1996/367) Amendment No.2: (Revoked by S.R. 1996/367) Amendment NO.3: S.R. 1990/221 Amendment No.4: S.R. 1991/134 Amendment NO.5: S.R. 1992/43 Amendment NO.6: S.R. 1994/299 Amendmem No.7: 5 R 1996/367 Amendment 1997: S.R.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Structure and Properties of X-Ray Contrast Media
    STRUCTURE AND PROPERTIES OF X-RAY CONTRAST MEDIA Optimal use of CM in radiology requires a knowl- edge of the nature and relevant properties of the available substances. This chapter describes the properties of currently used and newly developed contrast-giving agents that infuence their behav- ior in the human body, their side effects, and their practical utility. The main X-ray contrast agents in use today are insoluble barium sulfate for the diagnostic evalu- ation of the GI tract and water-soluble CM for the radiological assessment of the different vascular systems, body cavities and organs. In addition, a water-soluble CM based on tri-iodobenzene is the alternative agent of choice for oral use when bari- um sulfate is contraindicated. Barium Sulfate Barium is used in the form of the insoluble sulfate for radiography of the GI tract. If perforation is suspected, however, only water-soluble, iodinated agents (Gastrografn, Ultravist-370) can be used since the body is virtually incapable of eliminating barium sulfate once it has entered the peritoneum. Barium sulfate is available either as a powder to be prepared directly before use or as a ready-to-use suspension. For double-contrast examinations (fll- ing of the lumen with gas, coating of the wall with barium sulfate), barium sulfate is either mixed with a carbon dioxide additive, or a gas-forming agent is taken in addition. © The Author(s) 2018 20 U. Speck, X-Ray Contrast Media, https://doi.org/10.1007/978-3-662-56465-3_3 Common to all barium preparations is concentra- tion of barium sulfate which may diluted according to the needs of the examination.
    [Show full text]
  • (320 Mg I/Ml), Solution for Injection Meglumine Ioxaglate and Sodium Ioxaglate
    HEXABRIX 320 (320 mg I/mL), solution for injection Meglumine ioxaglate and sodium ioxaglate Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What HEXABRIX 320, solution for injection is and what it is used for 2. What you need to know before you use HEXABRIX 320, solution for injection 3. How to use HEXABRIX 320, solution for injection 4. Possible side effects 5. How to store HEXABRIX 320, solution for injection 6. Contents of the pack and other information 1. WHAT HEXABRIX 320 IS AND WHAT IT IS USED FOR HEXABRIX 320 is a contrast agent. It belongs to the group of contrast agents used for radiological examinations. HEXABRIX 320 is used to enhance the contrast of the images obtained during these examinations, in order to improve the visualisation and delineation of certain parts of the body, such as: Certain hollow organs (opacification of body cavities), The uterus and fallopian tubes (ducts connecting the uterus to the ovaries) in female patients (hysterosalpingography), Blood vessels (angiography), Joints (arthrography), Urinary system (urography). This medicine is for diagnostic use only. 2.
    [Show full text]